Good
Partially Aligned
Patient Risk:
Info
Summary
Most mortality-warning-aligned claims are consistent with the provided label excerpts, but several statements (e.g., Child-Pugh C/hepatic impairment contraindication and clinical behavior) cannot be verified against the supplied label content, which only addresses all-cause mortality and limitations of use.
Category Scores
Accurate Statements
TYGACIL should be reserved for use when alternative treatments are not suitable.
Section 5.1 ALL-CAUSE MORTALITY: 'TYGACIL should be reserved for use in situations when alternative treatments are not suitable'.
Unsupported Statements
Tigecycline is contraindicated in patients with severe hepatic impairment classified as Child-Pugh class C.
The supplied label excerpts do not include contraindications or hepatic impairment/Child-Pugh details, so this specific contraindication claim is not supported by the provided prescribing information.
The tigecycline contraindication specifically applies to severe (Child-Pugh C) hepatic impairment.
Not supported because contraindications/Child-Pugh specificity are not present in the supplied excerpts.
For mild or moderate hepatic impairment, tigecycline is not listed as contraindicated in the same way as severe (Child-Pugh C) hepatic impairment.
Not supported because hepatic impairment category contraindication language is not provided in the supplied excerpts.
Child-Pugh class C generally corresponds to severe cirrhosis or markedly reduced hepatic function based on bilirubin, albumin, INR/prothrombin activity, ascites, and hepatic encephalopathy scores.
This is general correspondence/definition information and is not supported by the supplied label excerpts.
Because tigecycline is contraindicated in Child-Pugh C hepatic impairment, clinicians typically choose an alternative antibiotic if a patient is truly in the severe hepatic impairment category.
The label excerpt provided does not state this clinical decision pattern; 'reserved use when alternatives are not suitable' is supported, but the 'typically choose an alternative due to contraindication' portion is not.
Contradictions
Low
AI Statement
N/A
Label Reference
N/A
Important Omissions
Quantitative boxed-warning details for all-cause mortality (e.g., 4.0% vs 3.0%; adjusted risk difference 0.6% [95% CI 0.1, 1.2]; cause not established).
Importance:
Moderate
Limitations of use regarding not being indicated for hospital-acquired or ventilator-associated pneumonia (and associated greater mortality/decreased efficacy in a comparative trial).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The only label-supported safety instruction present is to reserve use when alternatives are not suitable. However, multiple claims about contraindications in Child-Pugh C hepatic impairment are not supported by the provided excerpts, and missing quantitative boxed-warning communication could reduce safety fidelity.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Unsupported contraindication/Child-Pugh C hepatic impairment claims are included, and key boxed-warning quantitative/limitations-of-use details are not reliably reproduced from the supplied label content.
Suggested Improvement
Restrict statements to what is present in the provided label excerpts (all-cause mortality boxed warning and 'reserved use' language; limitation of use for hospital-acquired/ventilator-associated pneumonia). Do not assert contraindications (e.g., Child-Pugh C) unless the contraindication language is present in the provided prescribing information.